Novartis announces age indication expansion for meningococcal vaccine

An article from Vaccine News Daily
August 6, 2013
Novartis announces age indication expansion for meningococcal vaccine

 

August 6, 2013 -- Novartis, a Basel, Switzerland-based healthcare solutions company, announced on Thursday that the U.S. Food and Drug Administration approved the company’s quadrivalent meningococcal vaccine for children as young as two months of age.

With the expanded indication, U.S. pediatricians can now offer Menveo oligosaccharide diphtheria CRM197 conjugate vaccine to protect infants against four of the five most common meningococcal serogroups that cause meningococcal disease.

Read the rest of the article here.

Common Disease Taxonomy: 
Common Vaccine Taxonomy: